[go: up one dir, main page]

SG11201708401WA - Modified gamma delta cells and uses thereof - Google Patents

Modified gamma delta cells and uses thereof

Info

Publication number
SG11201708401WA
SG11201708401WA SG11201708401WA SG11201708401WA SG11201708401WA SG 11201708401W A SG11201708401W A SG 11201708401WA SG 11201708401W A SG11201708401W A SG 11201708401WA SG 11201708401W A SG11201708401W A SG 11201708401WA SG 11201708401W A SG11201708401W A SG 11201708401WA
Authority
SG
Singapore
Prior art keywords
gamma delta
delta cells
modified gamma
modified
cells
Prior art date
Application number
SG11201708401WA
Other languages
English (en)
Inventor
Michael David Leek
Adele Hannigan
Agapitos Patakas
Daria Paruzina
Original Assignee
Tc Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53333850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201708401W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2015/051985 external-priority patent/WO2016005752A1/en
Application filed by Tc Biopharm Ltd filed Critical Tc Biopharm Ltd
Publication of SG11201708401WA publication Critical patent/SG11201708401WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201708401WA 2015-04-15 2016-04-14 Modified gamma delta cells and uses thereof SG11201708401WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506423.1A GB201506423D0 (en) 2015-04-15 2015-04-15 Gamma delta T cells and uses thereof
PCT/GB2015/051985 WO2016005752A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof
PCT/GB2016/051050 WO2016166544A1 (en) 2015-04-15 2016-04-14 Modified gamma delta cells and uses thereof

Publications (1)

Publication Number Publication Date
SG11201708401WA true SG11201708401WA (en) 2017-11-29

Family

ID=53333850

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201708401WA SG11201708401WA (en) 2015-04-15 2016-04-14 Modified gamma delta cells and uses thereof

Country Status (15)

Country Link
US (2) US10881688B2 (he)
EP (1) EP3283620B1 (he)
JP (2) JP6995624B2 (he)
KR (1) KR20180012754A (he)
CN (2) CN107810267B (he)
AU (2) AU2016250211B2 (he)
BR (1) BR112017022249A2 (he)
CA (1) CA2982523A1 (he)
EA (1) EA201792041A1 (he)
ES (1) ES2993441T3 (he)
GB (1) GB201506423D0 (he)
IL (1) IL255011B (he)
SG (1) SG11201708401WA (he)
WO (1) WO2016166544A1 (he)
ZA (1) ZA201706922B (he)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
ES2910709T3 (es) 2015-09-03 2022-05-13 Uab Res Found Células T modificadas genéticamente resistentes a fármacos y procedimientos de utilización de las mismas
EP3516043A1 (en) * 2016-09-26 2019-07-31 Tessa Therapeutics Pte. Ltd. T cell expansion method
JP2020500903A (ja) 2016-12-09 2020-01-16 ザ ユーエイビー リサーチ ファウンデーション キメラクロロトキシン受容体
GB201701332D0 (en) * 2017-01-26 2017-03-15 Tc Biopharm Ltd Immune cells with modified metabolism and their use thereof
EP3580331B1 (en) 2017-02-08 2022-06-01 Agency For Science, Technology And Research Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
AU2018268087B2 (en) * 2017-05-18 2022-03-17 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
SG11202000606TA (en) * 2017-07-29 2020-02-27 Juno Therapeutics Inc Reagents for expanding cells expressing recombinant receptors
GB201715918D0 (en) 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN108085341A (zh) * 2017-12-28 2018-05-29 河南省华隆生物技术有限公司 一种msgv重组载体及其制备方法和应用
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
CN108588023B (zh) * 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
CN110577932A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 一种脐带血来源的嵌合抗原受体t细胞
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
AU2019354391A1 (en) * 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non- engineered γδ-Τ cells for treatment of hematological tumors
EP3860716A2 (en) * 2018-10-01 2021-08-11 Adicet Bio Inc. Compositions and methods regarding engineered and non-engineered gamma-delta -t cells for treatment of solid tumors
MX2021005242A (es) * 2018-11-05 2021-06-08 Xyphos Biosciences Inc Receptores nkg2d no naturales que no señalizan directamente las células a las que se unen.
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
JP7429882B2 (ja) * 2018-12-19 2024-02-09 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キメラ抗原受容体を発現する粘膜関連インバリアントｔ（ｍａｉｔ）細胞
CN109609465A (zh) * 2018-12-29 2019-04-12 武汉波睿达生物科技有限公司 一种利用脐血来源的γδT细胞制备CAR-T细胞的方法及该CAR-T细胞和应用
CN109762843A (zh) * 2018-12-29 2019-05-17 武汉波睿达生物科技有限公司 一种利用脐血来源的cd3阳性t细胞制备通用car-t细胞的方法
BR112021017537A2 (pt) 2019-03-05 2021-12-14 Nkarta Inc Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia
WO2020216238A1 (en) * 2019-04-22 2020-10-29 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
US20210048442A1 (en) 2019-08-13 2021-02-18 Immatics Biotechnologies Gmbh Method for the characterization of peptide:mhc binding polypeptides
AU2020334287A1 (en) * 2019-08-16 2022-02-24 GammaDelta Therapeutics Limited Ex vivo gamma delta T cell populations
CN114222585A (zh) * 2019-08-16 2022-03-22 伽马三角洲疗法有限公司 抗TCRδ可变1抗体的治疗用途
CN110964698B (zh) * 2019-12-25 2022-05-10 杭州中赢生物医疗科技有限公司 一种人工抗原递呈细胞及其制备方法和应用
US20230226183A1 (en) * 2020-01-15 2023-07-20 The Regents Of The University Of California Compositions and methods for altering gamma delta t cell activity
EP4110901A1 (en) * 2020-02-24 2023-01-04 immatics US, Inc. Methods for expanding t cells for the treatment of cancer and related malignancies
CN115485369A (zh) * 2020-03-03 2022-12-16 詹森生物科技公司 γδT细胞及其用途
CN115605212A (zh) * 2020-03-20 2023-01-13 伽玛德治疗有限公司（Gb） 用于治疗髓系恶性肿瘤的Vδ1+T细胞
JP7699154B2 (ja) 2020-05-22 2025-06-26 重▲慶▼精准生物技▲術▼有限公司 腫瘍微小環境を逆転させる融合タンパク質及びその使用
CN115996733A (zh) * 2020-06-22 2023-04-21 南京传奇生物科技有限公司 用于免疫疗法的基因工程化γδT细胞
EP4182338A1 (en) 2020-07-17 2023-05-24 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
ES2943063T3 (es) * 2020-08-14 2023-06-08 Gammadelta Therapeutics Ltd Anticuerpos multiespecíficos anti-TCR delta variable 1
CN114591907A (zh) * 2020-12-03 2022-06-07 复旦大学 一种γδT细胞的制备和扩增方法以及应用
CN112481284B (zh) * 2020-12-07 2023-07-25 深圳瑞吉生物科技有限公司 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用
CN114685684A (zh) * 2020-12-31 2022-07-01 博生吉医药科技(苏州)有限公司 MUC1-Tn嵌合抗原受体修饰的Vγ9Vδ2T细胞及其应用
AU2022222299A1 (en) 2021-02-17 2023-09-07 F-Star Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
AU2022224391A1 (en) * 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies
CN117120597A (zh) * 2021-04-06 2023-11-24 北京清辉联诺生物科技有限责任公司 提高γδ T细胞病毒转导稳定性的方法及其应用
CA3214941A1 (en) * 2021-04-16 2022-10-20 Ching-Wen Hsiao Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof
CN113156142B (zh) * 2021-04-16 2024-09-27 苏州才博医学科技有限公司 一种针对异体cart细胞特异性抗体的检测方法
JP2024519869A (ja) * 2021-05-19 2024-05-21 セレディット エルエルシー 二重特異性キメラ抗原受容体、及びそれを発現する遺伝子操作された免疫細胞
TW202306997A (zh) 2021-06-16 2023-02-16 英商英斯特生物科技有限公司 用於在過繼細胞療法中提供標靶共刺激之受體
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
CN113667640B (zh) * 2021-08-27 2022-09-02 广州百暨基因科技有限公司 CAR-γδT细胞的制备方法
EP4419118A4 (en) * 2021-10-20 2025-04-30 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
EP4479083A1 (en) 2022-02-16 2024-12-25 Priothera SAS Methods of treatment with car cells in combination with s1p receptor modulators
CN114645022B (zh) * 2022-05-13 2022-09-02 首都医科大学宣武医院 靶向CD5的CAR-γ δ T细胞及其制备方法与应用
JP2025520155A (ja) * 2022-06-01 2025-07-01 センス リサーチ ファウンデーション ガンマデルタｔ細胞による老化細胞の標的除去
CN116813794B (zh) * 2023-02-27 2024-07-12 武汉波睿达生物科技有限公司 共表达spi1的嵌合抗原受体及其应用
EP4458412A1 (en) 2023-05-05 2024-11-06 University College Cardiff Consultants, Ltd. Novel phosphoantigen prodrug compound and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771710B2 (en) 1999-01-28 2004-04-01 Palmetto Health Alliance D/B/A Palmetto Richland Memorial Hospital In vitro activated gamma delta lymphocytes
WO2001075072A2 (en) 2000-04-03 2001-10-11 Hemosol Inc. PRODUCTION OF TcR GAMMA DELTA T CELLS
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
WO2006006720A1 (ja) 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
NZ553055A (en) 2004-08-19 2008-12-24 Univ Cardiff Preparation of antigen-presenting human gamma delta T cells and use in immunotherapy
ES2391573T3 (es) 2005-09-08 2012-11-27 Medinet Co., Ltd. Método para el tratamiento de activación de una célula presentadora de antígeno
WO2008152822A1 (ja) 2007-06-15 2008-12-18 Medinet Co., Ltd. 医薬
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
NZ750426A (en) 2013-02-06 2020-06-26 Celgene Corp Modified t lymphocytes having improved specificity
CN112795594A (zh) 2013-05-14 2021-05-14 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
AU2014339926B2 (en) 2013-10-25 2018-02-08 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
WO2015066262A1 (en) 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
EP3071222B1 (en) 2013-11-21 2020-10-21 UCL Business Ltd Cell
RU2753965C2 (ru) 2014-02-14 2021-08-24 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Химерные антигенные рецепторы и способы их получения
ES2939760T3 (es) * 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
CA2954546A1 (en) 2014-07-09 2016-01-14 Tc Biopharm Ltd Gamma delta t cells and uses thereof
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
MX2017006408A (es) 2014-11-17 2018-03-23 Adicet Bio Inc Linfocitos t gamma delta modificados geneticamente.
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN105158466B (zh) * 2015-05-05 2017-12-22 中国科学院广州生物医药与健康研究院 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法

Also Published As

Publication number Publication date
ES2993441T3 (en) 2024-12-30
EA201792041A1 (ru) 2018-04-30
US20210252055A1 (en) 2021-08-19
EP3283620B1 (en) 2024-08-28
WO2016166544A1 (en) 2016-10-20
US10881688B2 (en) 2021-01-05
HK1250741A1 (en) 2019-01-11
CN107810267B (zh) 2022-03-04
CN107810267A (zh) 2018-03-16
JP2018512161A (ja) 2018-05-17
BR112017022249A2 (pt) 2018-07-10
EP3283620A1 (en) 2018-02-21
IL255011A0 (he) 2017-12-31
CA2982523A1 (en) 2016-10-20
AU2016250211B2 (en) 2022-03-03
AU2022203664A1 (en) 2022-06-16
JP2022046549A (ja) 2022-03-23
ZA201706922B (en) 2023-06-28
IL255011B (he) 2021-09-30
JP6995624B2 (ja) 2022-02-21
AU2016250211A1 (en) 2017-11-02
CN114717194A (zh) 2022-07-08
KR20180012754A (ko) 2018-02-06
US20180125889A1 (en) 2018-05-10
GB201506423D0 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
IL255011B (he) תאי גמה דלתא שעברו שינוי ושימושיהם
IL249970A0 (he) תאי טי גמא דלתא ושימושיהם
IL286785B (he) אנזימים ויישומים שלהם
IL259586A (he) תאי גזע שעברו שינוי גנטי ושימושים בהם
IL254734A0 (he) תאי t שעברו שינוי ושיטות להכנתם ולשימוש בהם
SG10201912576PA (en) Natural killer cells and ilc3 cells and uses thereof
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
IL297057B1 (he) צירופים ושימושים בהם
IL254241A0 (he) Etv2 ושימושים בו
IL273247A (he) שורת תאים חדשה ושימושיה
IL258042B2 (he) Tcr ושימושים בו
PL3387139T3 (pl) Beta-glukozydaza i jej zastosowania
IL254287A0 (he) אנלוגים של גאלאנין ציקליים ושימושים בהם
IL250272A0 (he) אנזים ללא שייר סוכרי ושימושיו
GB201604427D0 (en) Modified cell
GB201415379D0 (en) Gamma T cells and uses thereof
GB201412175D0 (en) Gamma T cells and uses thereof
GB201616232D0 (en) Novel cell line and uses thereof
GB201622225D0 (en) Modified host cells and uses thereof
HK1261250A1 (en) Modified immune cells and uses thereof
AU2015904933A0 (en) Genetically modified cells and uses thereof
AU2015904935A0 (en) Genetically modified cells and uses thereof - II
HUP1500514A2 (en) New ppv1 strain and uses thereof
GB201420709D0 (en) Electrochemical cells and components thereof